Danaher's Q3 Earnings Boosted By Bioprocessing Order Growth, Analyst Maintain Stock Rating
Portfolio Pulse from Vandana Singh
Danaher Corp (NYSE:DHR) reported Q3 sales of $5.79 billion, surpassing expectations. Despite a positive bioprocessing order growth, the company forecasts a slight decline in 2024 core revenue. Analysts maintain their ratings, with William Blair keeping an Outperform rating and Goldman Sachs a Neutral rating with a $250 price target. DHR stock fell 4.01% to $261.18.
October 22, 2024 | 7:28 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Danaher reported Q3 sales of $5.79 billion, exceeding expectations. Despite positive bioprocessing order growth, 2024 core revenue is expected to decline slightly. Analysts maintain ratings, with William Blair at Outperform and Goldman Sachs at Neutral with a $250 target. DHR stock fell 4.01%.
Danaher's Q3 sales exceeded expectations, which is positive. However, the forecasted decline in 2024 core revenue and the stock's 4.01% drop suggest mixed investor sentiment. Analysts' ratings remain unchanged, indicating a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100